{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T13:19:32Z","timestamp":1788182372104,"version":"build-2803163510"},"reference-count":24,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Addict"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background and Objectives<\/jats:title><jats:p>Medetomidine is a sedative approved by the FDA for veterinary use, but it is not authorized for human use. Its increasing presence alongside illegal opioids like fentanyl contributes to a rise in fatal overdoses across the U.S. While it is more potent than xylazine, knowledge surrounding medetomidine's role as an adulterant remains limited. This review investigates existing human data regarding its illicit use and overdose symptoms and highlights the evolving issue.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This review compiles case reports, law enforcement findings, and human studies to assess the role of medetomidine in opioid overdoses. We emphasize overdose symptoms, treatment challenges, and clinical outcomes, drawing from cases in U.S. cities experiencing rising overdose rates associated with this sedative.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The review reveals a troubling trend of increasing fatalities related to medetomidine adulteration, particularly in urban areas. Medetomidine's sedative effects complicate the management of opioid overdoses, often leaving many cases unrecognized due to the overlap of symptoms. The rising incidents of seizures and deaths underscore the urgent need for public health action.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion and Conclusions<\/jats:title><jats:p>The growing use of medetomidine as an opioid adulterant calls for further research, increased awareness among healthcare professionals and emergency responders, and enhanced diagnostic screening methods. Specific treatment protocols for medetomidine overdoses are crucial, and laboratory testing should be expanded to identify this substance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Scientific Significance<\/jats:title><jats:p>This review highlights the growing prevalence of medetomidine, which has surpassed xylazine also in some areas, and advocates for strengthened public health efforts to address this emerging crisis.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ajad.70030","type":"journal-article","created":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T04:45:52Z","timestamp":1742705152000},"page":"558-561","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Rise of illicit medetomidine use: A worrisome trend"],"prefix":"10.1111","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-9456-5828","authenticated-orcid":false,"given":"Nikhil","family":"Sood","sequence":"first","affiliation":[{"name":"Department of Medicine Banner Gateway Medical Center Gilbert Arizona USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,3,20]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"National Center for Health Statistics. US overdose deaths decrease in 2023 first time since 2018. May 15 2024. Accessed September 23 2024https:\/\/www.cdc.gov\/nchs\/pressroom\/nchs_press_releases\/2024\/20240515.htm#:~:text=Provisional%20data%20from%20CDC%E2%80%99s%20National%2cdrug%20overdose%20deaths%20since%202018"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7330a3"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/0278-5846(89)90051-1"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1M310"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(88)90744-3"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.4c00583"},{"key":"e_1_2_9_8_1","unstructured":"Philadelphia Department of Public Health: Division of Substance Use Prevention and Harm Reduction health.Health alert. 2024.PhiladelphiaDepartmentofPublicHealthDivisionofSubstanceUsePreventionandHarmReductionhttps:\/\/hip.phila.gov\/document\/4421\/PDPH-HAN-0441A-05-13-24.pdf"},{"key":"e_1_2_9_9_1","unstructured":"KrotulskiAJ ShinefeldJ MoraffC et al.Medetomidine rapidly proliferating across USA \u2014 implicated in recreational opioid drug supply & causing overdose outbreaks. Center for Forensic Science Research and Education; 2024.https:\/\/www.cfsre.org\/nps-discovery\/public-alerts\/toxic-adulterant-alert-medetomidine-dexmedetomidine.https:\/\/www.cfsre.org\/nps-discovery\/public-alerts\/medetomidine-rapidly-proliferating-across-usa-implicated-in-recreational-opioid-drug-supply-causing-overdose-outbreaks"},{"key":"e_1_2_9_10_1","doi-asserted-by":"crossref","unstructured":"SiscoE AppleyM.Identification of the veterinary sedative medetomidine in combination with opioids and xylazine in Maryland.Forensic Chem.2023[online].doi:10.1111\/1556-4029.15242","DOI":"10.26434\/chemrxiv-2023-c4q7f"},{"key":"e_1_2_9_11_1","unstructured":"Michigan Health & Hospital Association.New drug linked to overdose deaths across Michigan. 2024.https:\/\/www.mha.org\/newsroom\/new-drug-linked-to-overdose-deaths-across-michigan\/#:~:text=All%20three%20decedents%20also%20tested such%20as%20naloxone%20or%20Narcan"},{"key":"e_1_2_9_12_1","unstructured":"National Forensic Laboratory Information System. 2023.https:\/\/www.nflis.deadiversion.usdoj.gov\/nflisdata\/docs\/12557NFLISSnapshot2023March.pdf"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.15992"},{"key":"e_1_2_9_14_1","unstructured":"Philadelphia Department of Public Health.Health update. 2022.https:\/\/hip.phila.gov\/document\/3154\/PDPH-HAN_Update_13_Xylazine_12.08.2022.pdf\/"},{"key":"e_1_2_9_15_1","unstructured":"U.S. Food and Drug Administration.FDA approves new combination drug for sedation in dogs. 2022.https:\/\/www.fda.gov\/animal-veterinary\/cvm-updates\/fda-approves-new-combination-drug-sedation-dogs"},{"key":"e_1_2_9_16_1","doi-asserted-by":"crossref","unstructured":"JonesS BaileyS. Xylazine Test Stripsxylazine test strips for Drug Checkingdrug checking CADTH Horizon Scan [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health.2023.https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK595122\/","DOI":"10.51731\/cjht.2023.691"},{"key":"e_1_2_9_17_1","article-title":"An analytical platform for near real\u2010time drug landscape monitoring using paraphernalia residues","author":"Appley MG","year":"2022","journal-title":"ChemRxiv"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7217a2"},{"issue":"7","key":"e_1_2_9_19_1","first-page":"524","article-title":"Accidental human poisoning with a veterinary tranquilliser","volume":"22","author":"Cummins FH","year":"2005","journal-title":"Emerg Med J: EMJ"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2024.08.036"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5049.115617"},{"key":"e_1_2_9_22_1","unstructured":"Philadelphia Department of Public Health: Division of Substance Use Prevention and Harm Reduction.Health alert. 2024.https:\/\/hip.phila.gov\/document\/4874\/PDPH-HAN-00444A-12-10-2024.pdf\/?"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2020.10.024"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/PCC.0000000000003376"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.3390\/ani10071240"}],"container-title":["The American Journal on Addictions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajad.70030","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T12:04:58Z","timestamp":1757419498000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajad.70030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,20]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1111\/ajad.70030"],"URL":"https:\/\/doi.org\/10.1111\/ajad.70030","archive":["Portico"],"relation":{},"ISSN":["1055-0496","1521-0391"],"issn-type":[{"value":"1055-0496","type":"print"},{"value":"1521-0391","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,20]]},"assertion":[{"value":"2024-10-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}